Please login to the form below

Not currently logged in
Email:
Password:

The evolving biosimilars market

Safety and efficacy doubts remain a challenge

Laurent ChanrouxThe biosimilar market has continued to evolve rapidly in 2015, with the EMA's revised overarching guidelines on biosimilars coming into force and the FDA's approval of biosimilar filgrastim through the new biosimilars pathway (established under the Biologics Price Competition and Innovation Act).

Although these key regulatory developments are expected to greatly facilitate the approval of biosimilars in the near future, recent research from Research Partnership's Therapy Watch revealed that only 47% of rheumatologists interviewed would prescribe a biosimilar within the next six months, and that these agents might eventually only account for 12% of their biologic patients.

Our panel also highlighted the continued need for biosimilar manufacturers to address the remaining doubts about the safety and efficacy of these drugs and work with regulatory agencies and physician organisations to address the lack of clear treatment guidelines governing their use.

Laurent Chanroux

Laurentc@researchpartnership.com
+44 (0)20 8069 5016

21st July 2015

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....
Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...